Q-omics provides the consensus-scored RPL27P7 profile across patient tissues and cancer cell-line models. RPL27P7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RPL27P7 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, RPL27P7 RNA expression shows 6,632 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KICH, STAD, and BRCA as cancer lineages where RPL27P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL27P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL27P7 survival associations across molecular data types. RPL27P7 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL27P7 RNA expression–survival associations across cancer types. High RPL27P7 expression shows unfavorable associations in KICH, KIRC, DLBC and LIHC, but favorable associations in BLCA and ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RPL27P7 RNA expression.
This table summarizes RPL27P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL27P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL27P7 shows lower tumor expression in STAD, KIRC, THCA and LUSC and higher tumor expression in COAD and CHOL. The STAD box plot shows higher RPL27P7 RNA expression in normal versus tumor tissue (log2 FC = −0.329, t-test p = .017).
This table shows molecular features associated with RPL27P7 in patient tissues and cancer cell lines. In patient samples, RPL27P7 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
